Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

NCT07339488 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Borderline Resectable Carcinoma
Unresectable Cancer
Esophageal Squamous Cell Carcinoma (ESCC)
Immune Checkpoint Inhibitor
Chemotherapy
Radiotherapy
Tislelizumab

Interventions

RADIATION: Intestinal Low Dose Radiotherapy-1Gy
DRUG: PD-1/PD-L1 inhibitors
DRUG: Chemotherapy
PROCEDURE: Surgery

Sponsor

Chuangzhen Chen

Collaborators

BeOne Medicines